BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

933 related articles for article (PubMed ID: 23780685)

  • 21. Estrogen Enhances the Expression of the Multidrug Transporter Gene ABCG2-Increasing Drug Resistance of Breast Cancer Cells through Estrogen Receptors.
    Chang FW; Fan HC; Liu JM; Fan TP; Jing J; Yang CL; Hsu RJ
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28098816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells.
    Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE
    Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interleukin-1 beta and tumor necrosis factor-alpha increase ABCG2 expression in MCF-7 breast carcinoma cell line and its mitoxantrone-resistant derivative, MCF-7/MX.
    Mosaffa F; Lage H; Afshari JT; Behravan J
    Inflamm Res; 2009 Oct; 58(10):669-76. PubMed ID: 19333723
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unexpected Lower Expression of Oncoprotein Gankyrin in Drug Resistant ABCG2 Overexpressing Breast Cancer Cell Lines.
    Taheri T; Jamialahmadi K; Khadijeh F
    Asian Pac J Cancer Prev; 2017 Dec; 18(12):3413-3418. PubMed ID: 29286612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer.
    Hu Y; Qiu Y; Yagüe E; Ji W; Liu J; Zhang J
    Cell Death Dis; 2016 Jun; 7(6):e2291. PubMed ID: 27362808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epithelial cell adhesion molecule promotes breast cancer resistance protein-mediated multidrug resistance in breast cancer by inducing partial epithelial-mesenchymal transition.
    Shi RZ; He YF; Wen J; Niu YN; Gao Y; Liu LH; Zhang XP; Wang Y; Zhang XL; Zhang HF; Chen M; Hu XL
    Cell Biol Int; 2021 Aug; 45(8):1644-1653. PubMed ID: 33760350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transcriptional targeting of human liver carboxylesterase (hCE1m6) and simultaneous expression of anti-BCRP shRNA enhances sensitivity of breast cancer cells to CPT-11.
    Mishra MN; Vangara KK; Palakurthi S
    Anticancer Res; 2014 Nov; 34(11):6345-51. PubMed ID: 25368234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The function role of miR-181a in chemosensitivity to adriamycin by targeting Bcl-2 in low-invasive breast cancer cells.
    Zhu Y; Wu J; Li S; Ma R; Cao H; Ji M; Jing C; Tang J
    Cell Physiol Biochem; 2013; 32(5):1225-37. PubMed ID: 24335172
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression.
    Zhu J; Zou Z; Nie P; Kou X; Wu B; Wang S; Song Z; He J
    Cell Death Dis; 2016 Nov; 7(11):e2454. PubMed ID: 27809310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of indomethacin and dexamethasone effects on BCRP-mediated drug resistance in MCF-7 parental and resistant cell lines.
    Elahian F; Kalalinia F; Behravan J
    Drug Chem Toxicol; 2010 Apr; 33(2):113-9. PubMed ID: 20307139
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells: evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins.
    Diah SK; Smitherman PK; Aldridge J; Volk EL; Schneider E; Townsend AJ; Morrow CS
    Cancer Res; 2001 Jul; 61(14):5461-7. PubMed ID: 11454692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NP-1250, an ABCG2 inhibitor, induces apoptotic cell death in mitoxantrone-resistant breast carcinoma MCF7 cells via a caspase-independent pathway.
    Ito M; Kajino K; Abe M; Fujimura T; Mineki R; Ikegami T; Ishikawa T; Hino O
    Oncol Rep; 2013 Apr; 29(4):1492-500. PubMed ID: 23354844
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of BCRP mediated atypical multidrug resistance phenotype by RNA interference.
    Li WT; Zhou GY; Song XR; Chi WL; Ren RM; Wang XW
    Neoplasma; 2005; 52(3):219-24. PubMed ID: 15875083
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of 7-
    Chen Y; Li X; Shi L; Ma P; Wang W; Wu N; Gan Y; Han X; Huang S; Kang X; Liu S; Zhen Y
    Aging (Albany NY); 2022 Sep; 14(17):7156-7169. PubMed ID: 36107024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased fucosylation has a pivotal role in multidrug resistance of breast cancer cells through miR-224-3p targeting FUT4.
    Feng X; Zhao L; Gao S; Song X; Dong W; Zhao Y; Zhou H; Cheng L; Miao X; Jia L
    Gene; 2016 Mar; 578(2):232-41. PubMed ID: 26701615
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2.
    Kowalski P; Stein U; Scheffer GL; Lage H
    Cancer Gene Ther; 2002 Jul; 9(7):579-86. PubMed ID: 12082458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNA-574 enhances doxorubicin resistance through down-regulating SMAD4 in breast cancer cells.
    Sun FD; Wang PC; Luan RL; Zou SH; Du X
    Eur Rev Med Pharmacol Sci; 2018 Mar; 22(5):1342-1350. PubMed ID: 29565492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2.
    To KK; Robey RW; Knutsen T; Zhan Z; Ried T; Bates SE
    Mol Cancer Ther; 2009 Oct; 8(10):2959-68. PubMed ID: 19825807
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells.
    Kim M; Turnquist H; Jackson J; Sgagias M; Yan Y; Gong M; Dean M; Sharp JG; Cowan K
    Clin Cancer Res; 2002 Jan; 8(1):22-8. PubMed ID: 11801536
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel 5' untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-specific expression, and alternative promoter usage.
    Nakanishi T; Bailey-Dell KJ; Hassel BA; Shiozawa K; Sullivan DM; Turner J; Ross DD
    Cancer Res; 2006 May; 66(10):5007-11. PubMed ID: 16707421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.